Raymond James upgraded Revolution Medicines to Strong Buy from Outperform with a price target of $48, up from $36, after the company published data in peer reviewed journals and had numerous presentations at the 2024 American Association of Cancer Research Meeting. These updates increased conviction that Revolution “could have numerous blockbuster products with best-in-class potential,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
- Revolution Medicines announces publications on discovery of RMC-7977
- Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
- Revolution Medicines to Participate in Upcoming Investor Conferences
- Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
